Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Intellia Therapeutics Posts Back To Back Positive Data From Gene Editing Therapies

Published 16/09/2022, 14:26
© Reuters. Intellia Therapeutics Posts Back To Back Positive Data From Gene Editing Therapies

  • Intellia Therapeutics Inc (NASDAQ: NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ: NASDAQ:REGN) announced positive interim results from an ongoing Phase 1 trial of NTLA-2001, a CRISPR/Cas9 genome editing therapy for transthyretin (ATTR) amyloidosis.
  • The interim data include 12 ATTR amyloidosis adult patients with cardiomyopathy (ATTR-CM) with heart failure.
  • Interim data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 showed deep and sustained mean serum transthyretin (TTR) reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses, respectively.
  • Related: Intellia Therapeutics Shares Are Gaining After Positive Data From Second CRISPR Candidate.
  • At both dose levels, NTLA-2001 was generally well tolerated. Two of 12 patients reported transient infusion reactions.
  • One patient in the 0.7 mg/kg dose experienced a Grade 3 infusion-related reaction, which resolved without clinical consequence. No clinically significant liver findings were observed at either dose level.
  • A protocol amendment has been submitted to evaluate a fixed dose corresponding to 0.7 mg/kg in the dose-expansion portion, with enrollment across both arms expected to be completed by the end of 2022, subject to regulatory feedback.
  • Price Action: NTLA shares are down 4.13% at $65.75 during the premarket session on the last check Friday. REGN stock closed at $705.85 on Thursday.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.